Shanghai Bozhiyanxin Pharmaceutical Co., Ltd.

Main purpose To study the pharmacokinetics of a single oral dose of the test preparation of sildenafil citrate orodispersible film (specification: 50 mg) and the reference preparation of sildenafil citrate orodispersible film (trade name: Viagra®, specification: 50 mg) in healthy male subjects in China under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting and fed conditions. Secondary purpose 1. To observe the safety of the test preparation of sildenafil citrate orodispersible film and the reference preparation in healthy male subjects. 2. To evaluate the taste (palatability), oral dissolution time, mucosal adhesion and irritation of the test preparation of sildenafil citrate orodispersible film and the reference preparation.

Primary objective: To observe the in vivo pharmacokinetic process of dapnostat tablets after a single oral administration in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and use dapnostat tablets (trade name: Duvroq) licensed by Grakuso Smiscline Co., Ltd. and marketed in Japan as the original dosage form reference preparation for human bioequivalence evaluation. Secondary objective: To observe the safety of dapnostat tablets in healthy humans.

(1) Primary objective: To observe the pharmacokinetic characteristics of BCM894 capsules after single administration in healthy subjects in the fasting and fed states, and to investigate the effect of food on the pharmacokinetics of BCM894 capsules. (2) Secondary objective: To observe the safety of BCM894 capsules in healthy Chinese subjects.